4 minute read
Jan. 28, 2023

Resmetirom: A first-in-class drug for NASH?


once daily, oral THR β-selective agonist Ph. III for NASH opt. of triiodothyronine Lancet, December 17, 2022 Madrigal Pharmaceuticals, West Conshohocken, PA

Drug Hunter Team

A first-in-class drug for NASH? Resmetirom, an oral, liver-targeting, once-daily THR-β-selective agonist, recently made headlines for meeting both primary surrogate endpoints in an early Ph. III readout for NASH. How it works, where it came from, and why it matters...



Other molecules you may be interested in